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Introduction
The European Neuroendocrine Tumor Society (EN-ETS) proposed standard of care guidelines for pathology in 2009 [1] . Since then, profound changes in the classification have been made, dividing neuroendocrine neoplasia (NEN) into well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC) in the 2010 WHO classification [2] . The 7th edition of the TNM classification (2009) included NEN for the first time, widely adapting ENETS proposals but with some differences for NEC and for NET of the pancreas and the appendix [3] . Therapy guidelines for gastroenteropancreatic NET have recently been updated as well [4] . The need for an update of the standards of care prompted the ENETS to organize a consensus conference which was held in Antibes in 2015; a working group was designated to propose pathological standards of care.
Gross Analysis and Processing of Tissues
Histopathological analysis of tissue specimens is the gold standard for the diagnosis of NEN. Conventional morphological analysis is completed by immunohistochemistry, required to demonstrate the neuroendocrine phenotype and to evaluate the Ki-67 index. Samples can be obtained by endoscopy, but mini-biopsy is preferred to the classical fine-needle aspiration with smears only [5, 6] . Tissue specimens are gained by biopsy of a primary or secondary tumor, by surgical resection or by endoscopic resection. Tissues are fixed in formalin and embedded in paraffin. Resection specimens require a detailed gross examination to select the proper regions for histological analysis. Gross examination is also crucial to provide data for T and N staging and to select the regions to analyze for establishing resection status. Table 1 summarizes the mandatory and optional immunohistochemical requirements for a histopathological analysis of a NET biopsy. If by hematoxylin/eosin staining a neuroendocrine phenotype is suspected, immunohistochemical stainings for synaptophysin and chromogranin A are required to definitely confirm this hypothesis [7] . Cytokeratin staining might be useful to confirm the epithelial nature of the tumor and to rule out paraganglioma. In well-differentiated NET, all tumor cells stain diffusely for synaptophysin because of the diffuse presence of small clear vesicles. The expression of chromogranin A is usually more heterogeneous in the cytoplasm of tumor cells, since it depends on the presence of large neurosecretory granules. Rectal NET may frequently stain negative for chromogranin A with most monoclonal antibodies of current use. Otherwise, care must be taken in diagnosing well-differentiated NET without any chromogranin A expression; other entities, such as solid pseudopapillary neoplasia of the pancreas, acinar cell carcinoma or adrenocortical neoplasms, must be ruled out. In poorly differentiated NEC, however, chromogranin A may be lacking. Moreover, in some small cell NEC, synaptophysin may also be focal or absent. In such tumors, the diagnosis of "small cell neuroendocrine carcinoma" is a diagnosis of exclusion. The use of other so-called neuroendocrine markers such as neuron-specific enolase or N-CAM (CD56) is discouraged due to their low specificity [8] .
Diagnostic Standards

Neuroendocrine Phenotype
Differentiation
According to the WHO classification, NEN are divided into well-differentiated NET and poorly differentiated NEC. Initially, the assumption was that all G1-G2 tumors were well-differentiated and all G3 tumors were poorly differentiated. However, well-differentiated NET can rarely have proliferation indexes >20%, especially in the pancreas. These patients survive longer than patients with poorly differentiated NEC [9] , but shorter than patients with well differentiated NET. This new entity has by some been classified as well-differentiated NET G3 [10] . These well-differentiated NET with a high proliferation index seem to be characterized by a regular network of fine vessels, an organoid growth pattern without expansile growth and absence of geographic necrosis or desmoplastic stroma. Well-differentiated morphology correlates with a Ki-67 index range of 20-50% [9] [10] [11] [12] . Therefore, the exact Ki-67 index as well as differentiation needs to be included into pathology reports. For NEC, small cell and large cell morphology should be described.
Grading
Once the neuroendocrine nature of a tumor is demonstrated, the proliferative activity has to be assessed using Ki-67 staining and performing a staining index. The percentage of positive tumor nuclei has to be assessed and reported. Grading is performed as defined in WHO and UICC/AJCC classifications ( Table 2 ). The Ki-67 index seems to be more accurate and reproducible than mitotic count [13, 14] and is the only counting possible on biopsy samples. Therefore, the Ki-67 index is regarded as compulsory and mitotic count as optional. Grading can be performed on primary tumors as well as on metastases, but some heterogeneity exists between both and between different metastases [15] [16] [17] ; the proliferation index is often higher in metastases. If not enough material for hotspot selection and analysis of 2,000 tumor cells is available, undergrading might occur [18] ; this is occurring in EUS-obtained mini-biopsies [5, 19] . Grading is not recommended on smears from fineneedle aspiration, but reliability is increasing in minibiopsies, also gained by endoscopic procedures [6] . The risk of undergrading decreases between 200 and 2,000 cells examined [19, 20] and was minimal when >2,000 cells were counted [20] . Finally, the amount of tissues needed depends on the purpose of the analysis. Only a limited number of cells is enough for discriminating well-differentiated NET G1/G2 from poorly differentiated NEC G3, but this might not be sufficient for an accurate grading.
Optional Diagnostic Markers
The use of optional or additional markers including hormones or transcription factors may be employed in the setting of neuroendocrine tumor metastases of an unknown primary site: serotonin and CDX2 positivity are in favor of a primary of the small intestine, islet-1 (Isl-1) ex- 199 pression is found in primaries of the pancreas and duodenum, and TTF1 in primaries of the lung and in medullary thyroid carcinoma [21] , the second together with calcitonin. All these markers are of no use in the setting of poorly differentiated NEC [22] .
Immunohistochemical detection of somatostatin receptors (SSTR), especially SSTR2, is feasible and indicated in the absence of in vivo somatostatin imaging studies [23, 24] . In the case of questionable vascular invasion, immunohistochemistry for endothelial cell markers such as CD34 or special stains for the visualization of vessel walls might be of help. Table 3 summarizes the minimum requirements for pathological reports of resection specimens or biopsy specimens of NEN.
Pathological Report
Needs for Research
MGMT (O6-methylguanin-DNA methyltransferase) expression or methylation may serve as a predictive marker of a response to temozolomide-based chemotherapy in PanNET. Clinical trials are on the way to address this issue. In the same regard, translational studies are needed to define biomarkers predicting response to other therapies such as targeted therapies or other chemotherapeutic strategies. The new category of NET G3 needs to be better defined pathologically, possibly by the inclusion of molecular markers in order to have a more solid basis to define the therapeutic consequences of this tumor type. At last, increasing molecular evidence may suggest a grouping of NET according to mutational, expression or methylation profiles, but so far no therapeutic strategies are based on these findings.
Conclusions
The proposed standard procedures for diagnosing NEN should now follow the WHO and TNM classification systems that are under revision. A standardized diagnosis is the basis for a standardized treatment as well as for studies to be comparable. 
